Congestive Heart Failure Market to Observe Impressive Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Novartis, Bayer, Eli Lilly, Otsuka, Cytokinetics, Mesoblast

Delveinsight Business Research LLP
The Congestive Heart Failure Market size in the 7MM was approximately USD 6,000 million in 2022 and it is projected to grow by 2032. As per DelveInsight, the Congestive Heart Failure Market is anticipated to evolve immensely in the coming years owing to the expected launch of emerging therapies, the rise in the number of cases of Congestive Heart Failure, the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.

The drug candidates by key players, such as Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Applied Therapeutics, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies and others that are under late- and mid-phase of clinical development have the potential to create a significant positive shift in Congestive Heart Failure market size and the treatment scenario.

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congestive Heart Failure market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Congestive Heart Failure drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Congestive Heart Failure treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Congestive Heart Failure: An Overview

Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. 

Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow toward the heart. HF initially causes shortness of breath and fatigue (tiredness) and the right side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.

Congestive Heart Failure Market Key Facts

Congestive heart failure cases are maximum found in the age group of 75–84 years, i.e., approximately 1.6 million in the US.

According to secondary findings, about 1.2 million people in Germany suffer from heart failure, and HF is present in about 13–29% of all patients with acute ischemic stroke.

Japanese men smoke cigarettes at twice the rate of American men and have higher cholesterol and higher blood pressure, yet they have about 30% the rate of heart disease as in the US.

The expanded approval of Jardiance is anticipated to rule over Entresto and Farxiga in the HFpEF segment.

Surrounded by a potential pipeline targeting the HFrEF patient population, Omecamtiv mecarbil, which is a myosin-binding peptide, could aid cardiac contractility. It is projected to capture a major market share compared to its competitors.

Congestive Heart Failure Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Congestive Heart Failure pipeline therapies. It also thoroughly assesses the Congestive Heart Failure market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Congestive Heart Failure drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Congestive Heart Failure Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Congestive Heart Failure epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Congestive Heart Failure epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Congestive Heart Failure Epidemiology, Segmented as –

Prevalent Population of Heart Failure in the 7MM (2019–2032)

NYHA class-specific diagnosed prevalent cases in the 7MM (2019–2032)

Gender-specific diagnosed prevalent cases of Heart Failure in the 7MM (2019–2032)

Diagnosed Prevalent Population of Heart Failure in the 7MM (2019–2032)

Age-specific diagnosed prevalent cases of Heart Failure in the 7MM (2019–2032)

Diagnosed prevalent cases of Heart Failure with Ejection Fraction in the 7MM (2019–2032)

Diagnosed Prevalent cases of Heart Failure associated with comorbidities in the 7MM (2019–2032)

Congestive Heart Failure Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Congestive Heart Failure market or expected to be launched during the study period. The analysis covers the Congestive Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Congestive Heart Failure drugs based on their sale and market share.

The report also covers the Congestive Heart Failure pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Congestive Heart Failure companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Congestive Heart Failure Market Will Evolve and Grow by 2032 @

Congestive Heart Failure Therapeutics Analysis

Congestive Heart Failure market has considerable growth opportunities across all countries. The lack of a cure and the need for more effective therapies for HFrEF and HFpEF provides a good opportunity to launch effective novel therapies and targeted treatments in the emerging pipeline to take over the current market.

Congestive Heart Failure Companies Actively Working in the Therapeutics Market Include

Otsuka Pharmaceutical





Novo Nordisk

Lexicon Pharmaceuticals


Bristol-Myers Squibb

Intra-Cellular Therapies

Tenax Therapeutics


Eli Lilly and Company

And Many Others

Emerging and Marketed Congestive Heart Failure Therapies Covered in the Report Include:

ENTRESTO: Novartis

JARDIANCE: Boehringer Ingelheim and Eli Lilly

KERENDIA (finerenone): Bayer

MOUNJARO (tirzepatide): Eli Lilly and Company

OPC-61815: Otsuka Pharmaceutical

Omecamtiv Mecarbil: Cytokinetics

AZD4831: AstraZeneca

Rexlemestrocel-L (Revascor): Mesoblast

Semaglutide 2.4 mg: Novo Nordisk

Sotagliflozin: Lexicon Pharmaceuticals

Furoscix (furosemide injection): scPharmaceuticals

HNO (Nitroxyl) Donor (BMS-986231): Bristol-Myers Squibb

Lenrispodun (ITI – 214): Intra-Cellular Therapies

Levosimendan: Tenax Therapeutics

CardiAMPCell Therapy: BioCardia

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Congestive Heart Failure Competitive Intelligence Analysis

4. Congestive Heart Failure Market Overview at a Glance

5. Congestive Heart Failure Disease Background and Overview

6. Congestive Heart Failure Patient Journey

7. Congestive Heart Failure Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Congestive Heart Failure Treatment Algorithm, Current Treatment, and Medical Practices

9. Congestive Heart Failure Unmet Needs

10. Key Endpoints of Congestive Heart Failure Treatment

11. Congestive Heart Failure Marketed Therapies

12. Congestive Heart Failure Emerging Drugs and Latest Therapeutic Advances

13. Congestive Heart Failure Seven Major Market Analysis

14. Attribute Analysis

15. Congestive Heart Failure Market Outlook (In US, EU5, and Japan)

16. Congestive Heart Failure Companies Active in the Market

17. Congestive Heart Failure Access and Reimbursement Overview

18. KOL Views on the Congestive Heart Failure Market

19. Congestive Heart Failure Market Drivers

20. Congestive Heart Failure Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Varicose Veins Market

“Varicose Veins Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Varicose Veins market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Varicose Veins market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: